WaveMan · Company
BPTH · Bio-Path Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BPTH Bio-path (BPTH) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001133818
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$37.0K
four quarters, 2017-01-01 to 2017-12-31
History
FY Dec 2024$37.0K
FY Dec 2023$37.0K
FY Dec 2022$37.0K
FY Dec 2021$37.0K
FY Dec 2020$37.0K
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020n/a
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020-$11.0M
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020n/a
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020n/a
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
History
FY Dec 2024-3,326%
FY Dec 2023-220.0%
FY Dec 2022-70.0%
FY Dec 2021-51.5%
FY Dec 2020-60.2%
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024-3,326%
Sep 2024-1,160%
Jun 2024-366.2%
Mar 2024-430.8%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
History
FY Dec 2024-278.6%
FY Dec 2023-167.6%
FY Dec 2022-65.2%
FY Dec 2021-48.5%
FY Dec 2020-55.6%
Mar 2026n/a
Sep 2025-611.7%
Jun 2025-420.1%
Mar 2025-483.9%
Dec 2024-278.6%
Sep 2024-263.3%
Jun 2024-199.2%
Mar 2024-217.0%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020n/a
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
History
FY Dec 2024-1,261%
FY Dec 2023-203.1%
FY Dec 2022-69.7%
FY Dec 2021-51.0%
FY Dec 2020-59.4%
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024-1,261%
Sep 2024-762.1%
Jun 2024-362.0%
Mar 2024-398.6%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020n/a
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020n/a
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020-3.4%
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
History
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
FY Dec 2021n/a
FY Dec 2020n/a
Mar 2026n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
Jun 2024n/a
Mar 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

BPTH Stock Sonar score 2/7 axes

Find similar shapesCompare
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 506
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
100
Inputs
  • Short interest, % of float+0.0% · 100 pct, sector of 814
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BPTH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.7%12M
-100%-52%-5%+43%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

Bio-path insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for BIO-PATH HOLDINGS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns BPTH: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in BPTH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BPTH planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
3 active
1
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122023-122022-122021-12
Operating income$-12.0M$-15.8M$-13.9M$-10.4M
Net income$-9.9M$-16.1M$-13.9M$-10.4M
EPS (diluted)-4.12-33.63-38.12-1.55
Operating cash flow$-10.6M$-11.5M$-15.1M$-9.9M
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies